Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT07431281 · ClinicalTrials.gov registry record · Phase 3
Sonesitatug Vedotin in Combination With Capecitabine With or Without Rilvegostomig in Participants With Advanced or Metastatic Gastric, Gastroesophageal Junction, or Esophageal Adenocarcinoma Expressing Claudin18.2
A Phase 3 study of Gastric Cancer and Esophageal Cancer, sponsored by AstraZeneca.
- Recruiting
- Registry status
- Phase 3
- Development phase
- 2,130
- Enrollment target
- 20
- Study locations
NCT07431281 is a Phase 3 study of Gastric Cancer and Esophageal Cancer that is actively recruiting participants, run by AstraZeneca. The registered enrollment target is 2,130 participants, above the 305-participant average among 153 other Gastric Cancer trials with a reported enrollment target (598% higher). The trial reports 20 study locations across 10 states.
The verdict
NCT07431281, a Phase 3 study of Gastric Cancer and Esophageal Cancer, is actively recruiting participants, sponsored by AstraZeneca.
- RECRUITING
- Registry status
- Phase 3
- Development phase
- 2,130 participants
- Enrollment target
- 20
- Study locations
Study Summary
The purpose of this study is to evaluate the efficacy and safety of sonesitatug vedotin in combination with capecitabine with or without rilvegostomig in first-line (1L) Claudin18.2 (CLDN18.2)-positive, human epidermal growth factor receptor 2 (HER2)-negative, gastric, gastroesophageal junction (GEJ), and esophageal adenocarcinoma.
Conditions Studied
Interventions
- DRUG Capecitabine
- DRUG Nivolumab
- DRUG 5-Fluorouracil
- DRUG Rilvegostomig
- DRUG Sonesitatug vedotin
Study Locations (20)
California
- Research Site - Duarte
- Research Site - La Jolla
- Research Site - Orange
- Research Site - Walnut Creek
Florida
- Research Site - Fort Myers
- Research Site - Jacksonville
- Research Site - St. Petersburg
- Research Site - West Palm Beach
Georgia
- Research Site - Atlanta
- Research Site - Atlanta
- Research Site - Atlanta
Illinois
- Research Site - Chicago
- Research Site - Niles
Kentucky
- Research Site - Lexington
- Research Site - Louisville
Arizona
- Research Site - Phoenix
Colorado
- Research Site - Lone Tree
Connecticut
- Research Site - New Haven
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 2,130 participants |
| Start Date | 2026-02-03 |
| Est. Completion | 2031-10-27 |
| Phase | Phase 3 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT07431281
The ClinicalTrials.gov registry entry for NCT07431281 describes a study currently listed as recruiting, categorized as Phase 3. The registered enrollment target is 2,130 participants, a figure that helps gauge the scale of data the investigators plan to collect, above the 305-participant average among 153 other Gastric Cancer trials with a reported enrollment target (598% higher). The listed sponsor is AstraZeneca, which has 1,285 total studies on file at ClinicalTrials.gov.
The record links to 3 conditions, with Gastric Cancer appearing as the primary indexed condition, and to 5 interventions - of which Capecitabine is the first listed.
NCT07431281 reports 20 study locations spanning 10 distinct geographic areas - top geographies include California, Florida, Georgia.
Frequently Asked Questions
What is clinical trial NCT07431281 about?
NCT07431281 is a clinical study titled "Sonesitatug Vedotin in Combination With Capecitabine With or Without Rilvegostomig in Participants With Advanced or Metastatic Gastric, Gastroesophageal Junction, or Esophageal Adenocarcinoma Expressing Claudin18.2". The purpose of this study is to evaluate the efficacy and safety of sonesitatug vedotin in combination with capecitabine with or without rilvegostomig in first-line (1L) Claudin18.2 (CLDN18.2)-positive, human epidermal growth factor receptor 2 (HER2)-negative, gastric, gastroesophageal junction (GEJ...
What is the current status of trial NCT07431281?
This trial is currently recruiting. It is a Phase 3 study. The enrollment target is 2,130 participants. The study started on 2026-02-03. Estimated completion is 2031-10-27.
What conditions does trial NCT07431281 study?
This clinical trial studies the following conditions: Gastric Cancer, Esophageal Cancer, Gastroesophageal Junction Adenocarcinoma.
What interventions are being tested in trial NCT07431281?
The interventions under investigation include: Capecitabine (DRUG), Nivolumab (DRUG), 5-Fluorouracil (DRUG), Rilvegostomig (DRUG), Sonesitatug vedotin (DRUG).
Who is sponsoring clinical trial NCT07431281?
This trial is sponsored by AstraZeneca, which has 1,285 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT07431281 being conducted?
This trial has 20 study locations across Arizona, California, Colorado, Connecticut, Delaware. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Gastric Cancer
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
-
A Phase Ⅲ Clinical Study of HLX22 in Combination With Trastuzumab and Chemotherapy for the Treatment of Gastroesophageal Junction and Gastric Cancer
RECRUITING · Phase 3
-
AZD0901 Compared With Investigator's Choice of Therapy in Participants With Second- or Later-line Advanced or Metastatic Gastric or Gastroesophageal Junction Adenocarcinoma Expressing Claudin18.2
RECRUITING · Phase 3
-
Study of TDXd, Chemotherapy, Pembrolizumab, and Trastuzumab in First-Line Metastatic HER2-Positive Gastric or Gastroesophageal Junction Cancer
RECRUITING · Phase 3
-
Bemarituzumab or Placebo Plus Chemotherapy in Gastric Cancers With Fibroblast Growth Factor Receptor 2b (FGFR2b) Overexpression
ACTIVE NOT RECRUITING · Phase 3
-
Bemarituzumab Plus Chemotherapy and Nivolumab Versus Chemotherapy and Nivolumab for FGFR2b Overexpressed Untreated Advanced Gastric and Gastroesophageal Junction Cancer.
ACTIVE NOT RECRUITING · Phase 3
-
Early Palliative Care With Standard Care or Standard Care Alone in Improving Quality of Life of Patients With Incurable Lung or Non-colorectal Gastrointestinal Cancer and Their Family Caregivers
COMPLETED · Phase 3
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.